Neoantigens in cancer immunotherapy: quantity vs. quality

Yochai Wolf*, Yardena Sameuls*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Traditional immunotherapies provide clinical benefits to only a few patients with solid tumors, highlighting the urgent need for more effective approaches. Traditional immunotherapies rely on the presentation of cancer antigens, with neoantigens being highly important in this context as they are specific to malignant tissue but not healthy tissue. The quantity of neoantigens is often associated with clinical benefit, but it cannot fully explain or predict patient response. In this Viewpoint, we highlight several qualitative aspects that should be considered in neoantigen-based therapy. We emphasize the distinction between private and recurrent neoantigens, discuss the importance of neoantigen clonality, and describe new subtypes of neopeptides that further diversify the potential of neoantigens in immunotherapy.

Original languageEnglish
Pages (from-to)1457-1459
Number of pages3
JournalMolecular Oncology
Volume17
Issue number8
DOIs
StatePublished - Aug 2023

Funding

FundersFunder number
Dwek Institute for Cancer Therapy Research
EKARD Institute for Cancer Diagnosis Research
Lemelbaum family
Weizmann-Brazil Tumor Bank
Pfizer
Melanoma Research Alliance937368
European Research Council
Rosetrees TrustMYIA\100002
Israel Science Foundation696/17
Horizon 2020622106, 770854

    Keywords

    • cancer immunotherapy
    • cancer microbiome
    • neoantigens
    • post-translational modifications
    • recurrent mutations
    • tumor heterogeneity

    Fingerprint

    Dive into the research topics of 'Neoantigens in cancer immunotherapy: quantity vs. quality'. Together they form a unique fingerprint.

    Cite this